You are viewing the site in preview mode

Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Fig. 3

Step-down of asthma background medication. aAdditional controller medications can be changed or their doses can be up-titrated or down-titrated at the discretion of the investigator. bIf the patient is not taking a combination of ICS/LABA and is taking a separate ICS and additional controller medication(s), reduce only the dose of ICS and maintain the same dose of the additional controller medication(s). ICS inhaled corticosteroid, LABA long-acting β2-agonist, OCS oral corticosteroid, PRN prescribed-as-needed, SABA short-acting β2-agonist

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us